Rebuilding the Damaged Heart: The Potential of Cytokines and Growth Factors in the Treatment of Ischemic Heart Disease

Cytokine therapy promises to provide a noninvasive treatment option for ischemic heart disease. Cytokines are thought to influence angiogenesis directly via effects on endothelial cells or indirectly through progenitor cell-based mechanisms or by activating the expression of other angiogenic agents....

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2010-10, Vol.56 (16), p.1287-1297
Main Authors: BEOHAR, Nirat, RAPP, Jonathan, PANDYA, Sanjay, LOSORDO, Douglas W
Format: Article
Language:English
Subjects:
Angiogenesis
Biological and medical sciences
Bone marrow
Cardiology
Cardiology. Vascular system
Cardiovascular disease
Coronary heart disease
Coronary Vessels - drug effects
Cytokines - pharmacology
Cytokines - therapeutic use
Drug therapy
Heart
Heart attacks
Humans
Intercellular Signaling Peptides and Proteins - pharmacology
Intercellular Signaling Peptides and Proteins - therapeutic use
Medical sciences
Myocardial Ischemia - drug therapy
Myocarditis. Cardiomyopathies
Neovascularization, Physiologic
Rodents
Treatment Outcome
Vascular endothelial growth factor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytokine therapy promises to provide a noninvasive treatment option for ischemic heart disease. Cytokines are thought to influence angiogenesis directly via effects on endothelial cells or indirectly through progenitor cell-based mechanisms or by activating the expression of other angiogenic agents. Several cytokines mobilize progenitor cells from the bone marrow or are involved in the homing of mobilized cells to ischemic tissue. The recruited cells contribute to myocardial regeneration both as a structural component of the regenerating tissue and by secreting angiogenic or antiapoptotic factors, including cytokines. To date, randomized, controlled clinical trials have not reproduced the efficacy observed in pre-clinical and small-scale clinical investigations. Nevertheless, the list of promising cytokines continues to grow, and combinations of cytokines, with or without concurrent progenitor cell therapy, warrant further investigation.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2010.05.039